These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8866634)

  • 1. Influence of age, frailty and liver function on the pharmacokinetics of brofaromine.
    Zeeh J; Fuchs L; Bergmann W; Antonin KH; Degel F; Bieck P; Platt D
    Eur J Clin Pharmacol; 1996; 49(5):387-91. PubMed ID: 8866634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of food on the disposition of the monoamine oxidase-A inhibitor brofaromine in healthy volunteers.
    Degen PH; Cardot JM; Czendlik C; Dieterle W
    Biopharm Drug Dispos; 1993 Apr; 14(3):209-15. PubMed ID: 8490109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography.
    Fritze J; Becker T; Ziegler V; Laux G; Bieck P; Sofic E; Riederer P
    J Neural Transm Suppl; 1990; 32():197-201. PubMed ID: 2089091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.
    Feifel N; Kucher K; Fuchs L; Jedrychowski M; Schmidt E; Antonin KH; Bieck PR; Gleiter CH
    Eur J Clin Pharmacol; 1993; 45(3):265-9. PubMed ID: 8276052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
    Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
    Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine.
    Jedrychowski M; Feifel N; Bieck PR; Schmidt EK
    J Pharm Biomed Anal; 1993 Mar; 11(3):251-5. PubMed ID: 8518326
    [No Abstract]   [Full Text] [Related]  

  • 7. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
    Fritze J; Becker T; Ziegler V; Laux G; Riederer P
    Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
    Rasmussen BB; Brøsen K
    Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection.
    Schneider W; Keller B; Degen PH
    J Chromatogr; 1989 Mar; 488(1):275-82. PubMed ID: 2715286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats.
    Wang X; Yeung JH
    J Pharm Pharmacol; 2010 Aug; 62(8):1077-83. PubMed ID: 20663043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
    Perera V; Gross AS; Xu H; McLachlan AJ
    J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats.
    Pingili R; Vemulapalli S; Mullapudi SS; Nuthakki S; Pendyala S; Kilaru N
    Drug Dev Ind Pharm; 2016; 42(7):1110-7. PubMed ID: 26530401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.
    Bel N; Artigas F
    Naunyn Schmiedebergs Arch Pharmacol; 1995 May; 351(5):475-82. PubMed ID: 7543977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2.
    Buters JT; Tang BK; Pineau T; Gelboin HV; Kimura S; Gonzalez FJ
    Pharmacogenetics; 1996 Aug; 6(4):291-6. PubMed ID: 8873215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.
    Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW
    Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
    Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
    Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brofaromine--a review of its pharmacological properties and therapeutic use.
    Volz HP; Gleiter CH; Waldmeier PC; Struck M; Möller HJ
    J Neural Transm (Vienna); 1996; 103(1-2):217-45. PubMed ID: 9026374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor.
    Akinyinka OO; Sowunmi A; Honeywell R; Renwick AG
    Eur J Clin Pharmacol; 2000 May; 56(2):153-8. PubMed ID: 10877010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human].
    Schoerlin MP; Guentert TW
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():11-7. PubMed ID: 2685852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.